NOG抗体;NOG Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13180(NOG Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13180(NOG Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

Noggin (NOG) antibodies are immunological tools used to detect and study the function of Noggin, a secreted glycoprotein crucial in embryonic development. Discovered in the early 1990s, Noggin acts as a key antagonist of bone morphogenetic proteins (BMPs), particularly BMP-4. by binding to them and preventing receptor activation. This inhibition is vital for neural induction, skeletal formation, and joint development. Dysregulation of Noggin has been implicated in developmental disorders, skeletal abnormalities, and certain cancers.

NOG antibodies are widely utilized in developmental biology and biomedical research to visualize Noggin expression patterns, quantify protein levels, or block its activity in experimental models. They enable investigations into Noggin's role in stem cell differentiation, tissue homeostasis, and disease mechanisms. For instance, studies using NOG antibodies have revealed its neuroprotective effects and regulatory functions in cartilage maintenance. Clinically, Noggin overexpression is associated with conditions like fibrodysplasia ossificans progressiva (FOP), while its suppression may contribute to tumor progression.

These antibodies are available in monoclonal or polyclonal forms, often validated for applications including Western blot, immunohistochemistry, and ELISA. Recent therapeutic strategies also explore Noggin-targeting antibodies to modulate BMP signaling pathways in regenerative medicine or cancer therapy. Research continues to refine antibody specificity and explore clinical translations, underscoring Noggin's multifaceted biological significance.